AbCellera Biologics Inc vs Nasdaq Inc — how do they compare? AbCellera Biologics Inc trades at $10.32 (market cap $2.99B), while Nasdaq Inc trades at $95.99 (market cap $53.11B). The key difference: Nasdaq Inc is far larger — about 17.8× AbCellera Biologics Inc's market cap, and Nasdaq Inc pays a 1.22% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | NDAQ | |
|---|---|---|
Market Cap | $2.99B | $53.11B |
Sector | Health | Financials |
52-Week High | $9.76 | $100.98 |
52-Week Low | $2.78 | $76.85 |
Enterprise Value | $2.58B | $59.57B |
Dividend Yield | — | 1.22% |
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
Nasdaq (NDAQ) trades at $95.92, up 0.31% on the day, with a bullish technical signal from moving averages and strong support at $95. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.07 exceeding expectations, and revenue growth accelerated to $8.26 billion in 2025. Recent news includes the acquisition of LeveL Markets, advancing its always-on markets strategy.
The outlook is positive, supported by analyst consensus of $109.20 price target and 61% buy ratings. Key opportunities include sustained revenue growth and strategic acquisitions, while risks involve competitive pressures and market volatility. The stock offers a dividend yield with recent payouts of $0.31 per share.
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →